---
title: "Rapport Therapeutics CEO Abraham Ceesay sells 8,210 common shares worth $328,018"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292811724.md"
description: "Rapport Therapeutics CEO Abraham Ceesay sold 8,210 common shares on July 14, 2026, under a Rule 10b5-1 plan. The transaction occurred at prices between USD 39.72 and USD 40.57 per share. Following this sale, his direct common stock holdings decreased to 539,817 shares."
datetime: "2026-07-15T20:15:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292811724.md)
  - [en](https://longbridge.com/en/news/292811724.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292811724.md)
---

# Rapport Therapeutics CEO Abraham Ceesay sells 8,210 common shares worth $328,018

-   Rapport Therapeutics CEO Abraham Ceesay sold 8,210 common shares on July 14, 2026 under a Rule 10b5-1 plan. \* Sales priced at USD 39.72 and USD 40.57 per share, based on weighted averages. \* Direct common stock holdings fell to 539,817 shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-304786), on July 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [RAPP.US](https://longbridge.com/en/quote/RAPP.US.md)

## Related News & Research

- [Rapport Therapeutics CEO Abraham Ceesay sells 51,499 shares worth $2.41 million](https://longbridge.com/en/news/295706967.md)
- [Renaissance Technologies LLC Sells 109,114 Shares of Rapport Therapeutics, Inc. $RAPP](https://longbridge.com/en/news/296325369.md)
- [Pelthos Therapeutics announces annual shareholder meeting](https://longbridge.com/en/news/296270309.md)
- [La Rosa Holdings sells 210 Series E preferred shares for $210,000 in private placement](https://longbridge.com/en/news/296229216.md)
- [Aquestive Therapeutics CEO Daniel Barber disposes of 25,000 common shares worth $107,168](https://longbridge.com/en/news/296265589.md)